Stivarga Articles
Bayer initiates Ph III Stivarga study in liver cancer; Sanofi enrolls sarilumab patients
15 May 2013
Regulatory briefs on Bayer's Stivarga, Boehringer/Lilly's empagliflozin and Pfizer's Xeljanz
26 March 2013
FDA expands use of Bayer and Onyx' Stivarga for advanced GIST
26 February 2013
Bayer initiates Ph III trail of Xarelto in cardiac event prevention; R&D day presentation
14 November 2012
News briefs: Bayer's Stivarga and AstraZeneca's Faslodex
30 October 2012
Early FDA approval for Bayer's Stivarga in advanced colorectal cancer
28 September 2012
Showing 1-8 of 8 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
